Baldwin Investment Management LLC Sells 440 Shares of Novo Nordisk A/S (NYSE:NVO)

Baldwin Investment Management LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 2.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,740 shares of the company’s stock after selling 440 shares during the quarter. Baldwin Investment Management LLC’s holdings in Novo Nordisk A/S were worth $1,870,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of NVO. World Investment Advisors LLC boosted its position in shares of Novo Nordisk A/S by 36.9% during the third quarter. World Investment Advisors LLC now owns 13,925 shares of the company’s stock valued at $1,655,000 after purchasing an additional 3,750 shares in the last quarter. Versant Capital Management Inc bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at $86,000. CWA Asset Management Group LLC purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter worth about $2,722,000. Doliver Advisors LP increased its stake in shares of Novo Nordisk A/S by 54.5% in the 4th quarter. Doliver Advisors LP now owns 16,225 shares of the company’s stock worth $1,396,000 after acquiring an additional 5,721 shares in the last quarter. Finally, Norman Fields Gottscho Capital Management LLC lifted its position in Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after acquiring an additional 19,870 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

NVO opened at $69.27 on Friday. The company’s 50-day simple moving average is $71.47 and its two-hundred day simple moving average is $87.78. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The stock has a market capitalization of $310.85 billion, a P/E ratio of 21.05, a P/E/G ratio of 0.90 and a beta of 0.61. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.54%.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of analyst reports. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Hsbc Global Res raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. Dbs Bank lowered Novo Nordisk A/S to a “sell” rating in a research report on Friday, April 25th. Finally, Guggenheim cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.